Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $97.22 USD
Change Today -1.13 / -1.15%
Volume 2.2M
NVS On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
OTC US
Mexico
SIX Swiss Ex
As of 8:04 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by NOVARTIS AG-SPONSORED ADR (NVS) in the last 6 months

Announced 07/29/15
Novartis AG, Three Innovative Clinical-Stage Development Programmes
Merger/Acquisition

Mereo BioPharma Group Limited acquired Three Innovative Clinical-Stage Development Programmes of Novartis AG (SWX:NOVN) in stock on July 29, 2015. The consideration will be paid by issuing share in Mereo. In addition Novartis will share in the success of the development of these compounds, including a share on milestones and royalties on future commercial sales. Robert Cantone, Daryn Grossman, Mary Consalvi, Daniel St. Onge, Julie Kim and Laura Goldsmith of Proskauer ...
Read More


NVS's price was unchanged after the transaction was announced on 07/29/15.
Investor / Buyer
Mereo BioPharma Group Limited
Creditor / Lender
Novartis AG
 
Announced 07/29/15
Mereo BioPharma Group Limited
Merger/Acquisition

Novartis AG (SWX:NOVN) agreed to acquire an unknown stake in Mereo BioPharma Group Limited on July 29, 2015. It will swap of clinical assets for equity with Mereo BioPharma Group Ltd. The deal involves compounds in areas of unmet medical need including BPS-804, to improve bone density in brittle bone syndrome, an orphan disease; BCT-197 for acute exacerbations in COPD, and BGS-649 for obese men with hypogonadotrophic hypogonadism to normalize testosterone levels. Under ...
Read More


NVS's price was unchanged after the transaction was announced on 07/29/15.
Investor / Buyer
Novartis AG
 
Announced 03/30/15
25.00M for Aduro BioTech, Inc.
Private Placement

Aduro BioTech, Inc. announced that it has received $25 million in a round of funding from new investor Novartis AG on March 30, 2015. As a result of the transaction, the investor has acquired 2.7% stake in the company. The investor has also committed to invest another $25 million at a future date,


NVS's price was unchanged after the transaction was announced on 03/30/15.
Investor / Buyer
Novartis AG
 
Announced 03/13/15
Valneva SE
Merger/Acquisition

GlaxoSmithKline plc (LSE:GSK) acquired 4.96% stake in Valneva SE (ENXTPA:VLA) from Novartis AG (SWX:NOVN) on March 3, 2015.


NVS's price was unchanged after the transaction was announced on 03/13/15.
Investor / Buyer
GlaxoSmithKline plc
Creditor / Lender
Novartis AG
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $97.22 USD -1.13

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $303.74 USD -4.27
Amgen Inc $151.78 USD -4.11
Gilead Sciences Inc $105.07 USD -2.71
Johnson & Johnson $93.98 USD -1.19
Nestle SA SFr.71.30 CHF +0.40
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 24.8x
Price/Sales 4.6x
Price/Book 3.0x
Price/Cash Flow 13.4x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.